Organization Profile

You just read:

Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR(12) rates of up to 90% among broad range of genotype 1b hepatitis C patients

News provided by

Bristol-Myers Squibb Canada

Apr 10, 2014, 07:05 ET